Turning Long-Term Care Into a Long-Term Career
There’s a severe shortage of people to care for older Americans. Could providing workers with new career pathways be part of the solution?
Read MoreLong-term Care
How Vaccine Mandates Helped Protect Nursing Homes and Their Staff
Jasmine Travers share new research that explores the effect of state vaccine mandates on vaccination rates and staffing changes in nursing homes.
Read More
The Complex Relationship Between Quality Ratings and Pandemic Deaths in Nursing Homes
Yaa Akosa Antwi shares research on nursing home deaths during COVID suggesting even well-intentioned policies can have unintended consequences.
Read More
How Nursing Home Staff Biases Drive Inequitable Care
Jasmine Travers shares research showing how racial biases can impact care for Black nursing home residents with advanced dementia.
Read More
Private Equity’s Impact on Nursing Home Quality
Rachel Werner on new research exploring how nursing homes with private equity investment compared to other nursing homes on cost, outcomes and staffing.
Read More
The Aducanumab Aftermath: The Industry
How is the pharmaceutical industry reacting to the FDA’s surprising approval of a controversial Alzheimer’s drug?
Read More
The Aducanumab Aftermath: The Payer
A costly new Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.
Read More
The Aducanumab Aftermath
The Aducanumab Aftermath A SPECIAL CONVERSATION SERIES June 22, 2021 Art by Leslie Walker About this Special Series The U.S. Food and Drug Administration (FDA) recently approved the costly new Alzheimer’s drug aducanumab (now known by the brand name Aduhelm) despite doubts about its safety and efficacy. Priced at $56,000 by drugmaker Biogen, aducanumab could…
Read More
The Aducanumab Aftermath: The Doctor
One doctor grapples with questions about a controversial new Alzheimer’s drug’s safety and efficacy.
Read More